The Relationship Web: AI + Life Sciences
An interactive map of 50 deals, partnerships, and acquisitions reshaping the intersection of AI and drug discovery — $90B+ deployed, 2018–2026.
An interactive force-directed network visualization mapping the AI × Life Sciences deal landscape.
What You're Looking At
This visualization maps 50 major transactions — acquisitions, partnerships, investments, and strategic alliances — at the intersection of artificial intelligence and life sciences, from 2018 through 2026.
How to Navigate
Click any node to highlight all connections for that company and see a ranked list of its deals.
Click any edge to see full deal details: value, date, motivation, and significance.
Drag nodes to rearrange the network. Scroll to zoom in or out.
What the Data Shows
The network reveals three structural dynamics shaping the AI × Life Sciences landscape:
Foundation models are becoming infrastructure. Anthropic and OpenAI have each signed 6+ pharma partnerships in 18 months. Veeva built its AI product on Claude. Thermo Fisher runs OpenAI APIs across its entire clinical research platform.
Drug discovery is consolidating. The Recursion-Exscientia merger ($688M) created a full-stack AI drug platform. Isomorphic Labs raised $600M Series A after the Lilly and Novartis deals. The acqui-hire of Coefficient Bio by Anthropic ($400M for 9 people) set a new ceiling for biology-AI talent pricing.
Big Pharma is racing to build data moats. Roche's $4.3B Flatiron + Foundation Medicine acquisition (2018) remains the template. Eli Lilly's $1B Nvidia co-innovation lab, the Novo Nordisk-Valo $4.6B partnership, and Sanofi's dual Anthropic/OpenAI partnerships all reflect the same thesis: proprietary data + AI access = durable competitive advantage.